https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49984 Wed 28 Feb 2024 15:55:05 AEDT ]]> ‘Breathing Fire’: Impact of Prolonged Bushfire Smoke Exposure in People with Severe Asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45438 Wed 20 Mar 2024 15:45:49 AEDT ]]> Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47085 Tue 13 Dec 2022 16:35:23 AEDT ]]> Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54560 Thu 29 Feb 2024 10:27:50 AEDT ]]> Severe asthma assessment, management and the organisation of care in Australia and New Zealand: expert forum roundtable meetings https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39023 Thu 21 Apr 2022 09:51:00 AEST ]]> Impact of Landscape Fire Smoke Exposure on Patients With Asthma With or Without Laryngeal Hypersensitivity https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53947 Mon 22 Jan 2024 16:56:55 AEDT ]]> Mepolizumab effectiveness and identification of super-responders in severe asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40118 Fri 22 Jul 2022 13:48:23 AEST ]]>